Description

Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore!

Incyte Corporation is reportedly close to acquiring privately held Star Therapeutics in a transaction valued at up to $2 billion, including about $1.25 billion in upfront cash and $750 million tied to future milestones. The deal would bring Star’s lead asset, VGA039, into Incyte’s portfolio at a critical point for the company. VGA039 is a late-stage, once-monthly injectable therapy for von Willebrand disease, the most common inherited bleeding disorder, and has received FDA Fast Track designation. The potential acquisition also comes shortly after Incyte reported a strong Q1 2026, with total revenue rising 21% year-over-year to $1.27 billion and net sales rising 20% to $1.1 billion, supported by growth across Jakafi, Opzelura, Niktimvo, Monjuvi and Zynyz. For new CEO Bill Meury, the move would fit a broader push to diversify beyond Jakafi before its expected 2028 patent expiration.